Search Results - "Crosby, Tom David Lewis"

Protocol for open-label, randomised, controlled trial of intensive surveillance vs. standard postoperative follow-up in patients undergoing surgical resection for oesophageal and gastric cancer (SARONG trial) by Markar, Sheraz, Guazzelli, Alice, Taylor, Amy, Lloyd Jones, Laura, Jogarah, Vidoushee, Cromwell, David, Landeiro, Filipa, Maynard, Nick, Lagergren, Jesper, Gleeson, Fergus, Underwood, Tim, Moss, Alan, Crosby, Tom David Lewis

“…TPS416 Background: Despite recent improvements in oncological and surgical treatment for patients with oesophageal and gastric cancer, 60% of patients with…”
Get full text

Role of nutritional status as predictor of survival in oesophageal cancer treated with definitive chemoradiation (dCRT): outcome from SCOPE1, a phase II/III randomised trial of dCRT +/- cetuximab by Cox, Samantha, Powell, Ceri, Carter, Ben, Hurt, Chris, Mukherjee, Somnath, Crosby, Tom David Lewis

“…Abstract only 103 Background: Malnutrition is common in oesophageal cancer and may be related to the disease or treatment. We aimed to identify nutritional…”
Get full text

Induction oxaliplatin capecitabine followed by switch to carboplatin-paclitaxel based RT versus continuing oxaliplatin capecitabine RT in operable esophageal adenocarcinoma: Survival analysis of the randomized phase II neoscope trial by Mukherjee, Somnath, Hurt, Chris, Cox, Catrin, Radhakrishna, Ganesh, Gwynne, Sarah, Bateman, Andrew Rea, Gollins, Simon, Hawkins, Maria A., Canham, Jo, Grabsch, Heike I., Falk, Stephen, Sharma, Ricky A., Ray, Ruby, Roy, Rajarshi, Wade, Wendy, Maggs, Rhydian, sebag-Montefiore, David joseph, Maughan, Tim, Griffiths, Gareth Owen, Crosby, Tom David Lewis

“…Abstract only 373 Background: Initial results of the NEOSCOPE trial comparing pre-operative CarPac vs OxCap based chemoradiotherapy (CRT) in patients with…”
Get full text

ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up by Neoptolemos, John P., Palmer, Daniel H., Ghaneh, Paula, Valle, Juan W., Cunningham, David, Wadsley, Jonathan, Meyer, Tim, Anthoney, Alan, Glimelius, Bengt, Falk, Stephen, Segersvard, Ralf, Middleton, Gary William, Ross, Paul J., Wasan, Harpreet Singh, McDonald, Alec, Crosby, Tom David Lewis, Psarelli, Eftychia Eirini, Hammel, Pascal, Hackert, Thilo, Buchler, Markus W.

“…Abstract only 4516 Background: The ESPAC-4 trial demonstrated that adjuvant GEM/CAP for pancreatic cancer significantly improved survival compared to GEM…”
Get full text

On-trial radiotherapy quality assurance in NeoSCOPE: A randomised phase II trial of chemoradiotherapy in oesophageal cancer by Evans, Elin, Jones, Gareth, Radhakrishna, Ganesh, Hawkins, Maria A, Mukherjee, Somnath, Maggs, Rhydian, Ray, Ruby, Crosby, Tom David Lewis, Gwynne, Sarah

“…Abstract only 119 Background: Failure to adhere to trial protocols for target volume delineation (TVD) within radiotherapy (RT) trials may have an adverse…”
Get full text

NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma by Mukherjee, Somnath, Hurt, Chris, Gwynne, Sarah, Bateman, Andrew, Gollins, Simon, Radhakrishna, Ganesh, Canham, Jo, Ray, Ruby, Grabsch, Heike I, Sharma, Ricky A., Maggs, Rhydian, Hawkins, Maria A, Sebag-Montefiore, David, Maughan, Tim, Griffiths, Gareth, Crosby, Tom David Lewis

“…Abstract only 3 Background: NEOSCOPE compared toxicity and efficacy of 2 pre-op CRT regimens. Methods: Eligibility: Resectable ACA of the oesophagus/GOJ ≥ T3…”
Get full text

Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT+C) in esophageal cancer by Mukherjee, Somnath, Hurt, Chris, Falk, Stephen, Gollins, Simon, Staffurth, John, Ray, Ruby, Bridgewater, John A., Cunningham, David, Blazeby, Jane M., Roy, Rajarshi, Maughan, Tim, Griffiths, Gareth, Crosby, Tom David Lewis

“…Abstract only 118 Background: One of the largest trials in dCRT for localised oesophageal cancer, SCOPE 1 tested the role of adding cetuximab to conventional…”
Get full text

ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma by Neoptolemos, John P., Palmer, Dan, Ghaneh, Paula, Valle, Juan W., Cunningham, David, Wadsley, Jonathan, Meyer, Tim, Anthoney, Alan, Glimelius, Bengt, Falk, Stephen, Segersvard, Ralf, Izbicki, Jakob R., Middleton, Gary William, Ross, Paul J., Wasan, Harpreet, Mcdonald, Alec, Crosby, Tom David Lewis, Psarelli, Eftychia Eirini, Hammel, Pascal, Buchler, Markus W.

“…Abstract only…”
Get full text

ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma by Neoptolemos, John P., Palmer, Dan, Ghaneh, Paula, Valle, Juan W., Cunningham, David, Wadsley, Jonathan, Meyer, Tim, Anthoney, Alan, Glimelius, Bengt, Falk, Stephen, Segersvard, Ralf, Izbicki, Jakob R., Middleton, Gary William, Ross, Paul J., Wasan, Harpreet, Mcdonald, Alec, Crosby, Tom David Lewis, Psarelli, Eftychia Eirini, Hammel, Pascal, Buchler, Markus W.

“…Abstract only LBA4006 Background: The ESPAC-3 trial compared adjuvant GEM with 5-fluorouracil/folinic acid for resected pancreatic cancer. GEM is the standard…”
Get full text

Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma by Waddell, Tom Samuel, Chau, Ian, Peckitt, Clare, Gonzalez, David, Wotherspoon, Andrew, Patel, Bijal, Middleton, Gary William, Wadsley, Jonathan, Ferry, David, Mansoor, Wasat, Crosby, Tom David Lewis, Coxon, Fareeda Y., Smith, David, Waters, Justin S., Iveson, Timothy, Falk, Stephen, Slater, Sarah, Okines, Alicia Frances Clare, Cunningham, David

“…Abstract only…”
Get full text

Prognostication in esophagogastric adenocarcinoma (OGA): Factors influencing overall survival (OS) in REAL3 by Waddell, Tom Samuel, Chau, Ian, Peckitt, Clare, Patel, Bijal, Gonzalez de Castro, David, Wotherspoon, Andrew, Middleton, Gary William, Wadsley, Jonathan, Ferry, David, Mansoor, Wasat, Crosby, Tom David Lewis, Coxon, Fareeda Y., Smith, David, Waters, Justin S., Iveson, Timothy, Falk, Stephen, Slater, Sarah, Okines, Alicia Frances Clare, Cunningham, David

“…Abstract only 91 Background: The REAL3 trial evaluated the addition of panitumumab (P) to epirubicin, oxaliplatin and capecitabine (EOC) in advanced OGA. We…”
Get full text

A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3) by Waddell, Tom Samuel, Chau, Ian, Barbachano, Yolanda, Gonzalez de Castro, David, Wotherspoon, Andrew, Saffery, Claire, Middleton, Gary William, Wadsley, Jonathan, Ferry, David Raymond, Mansoor, Wasat, Crosby, Tom David Lewis, Coxon, Fareeda Y, Smith, David, Waters, Justin S., Iveson, Timothy, Falk, Stephen, Slater, Sarah, Okines, Alicia Frances Clare, Cunningham, David

“…Abstract only LBA4000 Background: EGFR overexpression occurs in 27-50% of esophagogastric adenocarcinomas (OGA), and correlates with poor prognosis. The REAL3…”
Get full text

A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3) by Waddell, Tom Samuel, Chau, Ian, Barbachano, Yolanda, Gonzalez de Castro, David, Wotherspoon, Andrew, Saffery, Claire, Middleton, Gary William, Wadsley, Jonathan, Ferry, David Raymond, Mansoor, Wasat, Crosby, Tom David Lewis, Coxon, Fareeda Y, Smith, David, Waters, Justin S., Iveson, Timothy, Falk, Stephen, Slater, Sarah, Okines, Alicia Frances Clare, Cunningham, David

“…Abstract only LBA4000 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the…”
Get full text